AURTHUR GUERRERO
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism SCHERTZ, TX NPI 1346211604
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism TX Novo Nordisk AS All categories
General Payments — all program years on this page
$151,735.97
- Category: General Payments
- Program years: PY2018–2024
- Record count: 1,543
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $3,281.84 across 177 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,281.84 | 177 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $531.59 | 25 |
| DEXCOM, INC. | $313.73 | 9 |
| Lilly USA, LLC | $281.92 | 19 |
| Insulet Corporation | $215.21 | 36 |
| Amgen Inc. | $210.73 | 13 |
| Abbott Laboratories | $193.44 | 8 |
| Medtronic, Inc. | $187.50 | 4 |
| Radius Health, Inc. | $144.94 | 6 |
| ABBVIE INC. | $135.66 | 10 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $129.24 | 6 |
| CHIESI USA, INC. | $112.30 | 5 |
| BETA BIONICS, INC. | $110.86 | 4 |
| Amneal Pharmaceuticals LLC | $89.06 | 4 |
| SANOFI-AVENTIS U.S. LLC | $85.26 | 4 |
| EISAI INC. | $63.01 | 2 |
| CeQur Corporation | $62.12 | 1 |
| MannKind Corporation | $59.48 | 3 |
| Kyowa Kirin, Inc. | $45.77 | 2 |
| Corcept Therapeutics | $42.92 | 2 |
| BOSTON SCIENTIFIC CORPORATION | $36.59 | 1 |
| Currax Pharmaceuticals LLC | $35.21 | 2 |
| Esperion Therapeutics, Inc. | $33.09 | 2 |
| RECORDATI_RARE_DISEASES_INC. | $32.27 | 2 |
| PFIZER INC. | $31.41 | 2 |
| Tandem Diabetes Care, Inc. | $24.16 | 1 |
| Ascensia Diabetes Care US Inc. | $21.08 | 1 |
| Enterra Medical, Inc. | $20.20 | 1 |
| Xeris Pharmaceuticals, Inc. | $17.26 | 1 |
| Averitas Pharma Inc. | $15.83 | 1 |
By program year
Records — PY2024 (177)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.